You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

November 28, 2017

Thailand Food and Drug Administration Unveils New Official Fees

Subscribe to Updates
Informed Counsel

Higher life expectancy, a growing middle-income population, and the government’s policy of promoting access to medicine are key drivers boosting demand for healthcare-related businesses in Thailand. In 2015, healthcare expenditures accounted for 4.6 percent of Thailand’s GDP, and there is an increasing trend in government budgetary spending in healthcare. Due to these factors, the healthcare market is experiencing strong growth, bringing opportunities in cosmetics, health supplements, medical devices, and pharmaceuticals.

Nonetheless, a major obstacle for these industries is the slow-moving registration process of the Thai Food and Drug Administration (FDA). This registration process is a mandatory prerequisite for introducing new healthcare products to the Thai market.

There are currently thousands of drug registration dossiers under evaluation by the FDA that have been stalled under successive governments. A similar backlog has been found in the process to obtain licenses for moderate- to high-risk medical devices, novel foods, food supplements, and innovative herbal products.

The backlog of pending product approvals hinders industries from competing effectively in the market, and it impacts companies eager to launch their new products in a timely manner. More importantly, from a consumer standpoint, the slow approval process prevents Thais from being able to buy products at lower competitive prices and restricts access to the latest innovative drugs.

Delays in the approval process stem from the fact that the FDA lacks sufficient qualified officers to examine technical dossiers to assess the quality, efficacy, and safety of products. The FDA has difficulty in hiring qualified experts, and there are not enough specialists to handle the ever-increasing number of application dossiers.

Reforming the FDA Approval Process

In order to solve this backlog issue, the prime minister has exercised his power as head of the National Council for Peace and Order (NCPO) by using section 44 of the 2014 interim constitution to issue NCPO Order No. 77/2559 Re: Increasing the Efficiency of the Health Products Approval Process, which was published in the Government Gazette on December 28, 2016. The order directs that the FDA approval process for healthcare products must be reformed. The main implications of the order include the following:

  • The FDA’s product approval timeline must not exceed the time specified in its public manuals, which are handbooks that inform the public about the application procedures, relevant legislation, timelines, and list of documents needed for product registration at the FDA.
  • The FDA will consider the official fee schedule in its approval process. Official fees earned by the FDA will be used as honorariums for reviewers/experts to assess technical dossiers, as well as to improve the approval procedure, as per regulations of the Ministry of Finance. Unlike in the past, official fees earned by the FDA will not be refunded to the Ministry of Finance as government revenue.
  • The FDA will outsource some work, such as onsite inspections and evaluations of technical documents, to external experts of local or overseas agencies, who have been approved by and registered with the FDA.

New FDA Official Fees

The FDA engaged in over 10 meetings with major pharmaceutical companies to discuss the overhaul of its approval process and official fee schedule. Subsequently, the Ministry of Public Health (MoPH) issued MoPH Notification Re: Actual Official Fees in the Approval Process to Be Paid by the Applicant on August 4, 2017. The notification prescribes the highest rates of official fees and actual fees to be paid by applicants, with the highest rates to remain effective for 10 years, and revisions by the FDA allowed in five years.

In the past, the FDA approval process charged only one fee for obtaining a license. The new official fee schedule introduced by the MoPH notification itemizes fees to be incurred for each step of the application process, from filing the application, to dossier evaluation, to obtaining a license.

As of August 4, 2017, an applicant now pays THB 2,500 for filing an application, THB 182,500 for dossier evaluation, and THB 2,000 for obtaining the Marketing Authorization (MA) Drug Product License for a new chemical drug. The MoPH notification also prescribes fees covering the lifecycle of a drug product, including fees for an importation/manufacturing license, a sales license, an advertisement approval license, variations of these licenses, etc. More interestingly, the FDA now charges an hourly consultation fee of THB 500–2,000, depending on the consultation matter.

Healthcare business operators should closely monitor the registration and approval process reforms of the Thai FDA. Although the FDA’s official fees have increased substantially, product owners hoping to bring their new products to the Thai market are likely to benefit greatly from the invigorated registration process that promises drug product approval in a more timely and systematic manner.

Download Full Article
Related Professionals

Industries

Life Sciences

Practices

Regulatory Affairs

Location

RELATED INSIGHTS​ 

January 10, 2023
On January 9, 2023, Vietnam’s National Assembly voted to approve a draft resolution on the continued implementation of policies for the prevention and control of the Covid-19 pandemic. Under this resolution, marketing authorizations (MAs) for the following drugs and medicinal ingredients will be extended to December 31, 2024, allowing continued use in Vietnam: Drugs and medicinal ingredients whose MAs expire from January 1, 2023, to December 12, 2024, and whose extension dossiers have been submitted but have not yet been approved in accordance with the Law on Pharmacy; and Drugs and medicinal ingredients whose MAs have been extended as per Resolution No. 12/2021/UBTVQH15 and have not been extended in accordance with the Law on Pharmacy. The extension does not apply to the following cases: Drugs and medicinal ingredients that have been recalled by the Law on Pharmacy; Drugs with signs of being unsafe for users that have been suspended from circulation/use and sealed for preservation in accordance with the Law on Pharmacy; and Drugs with MAs having a validity term of three years in accordance with the Law on Pharmacy. The Ministry of Health will announce the list of drugs and medicinal ingredients whose MAs are subject to be extended as described above.
Read More
November 23, 2022
The delisting of cannabis as a controlled narcotic in Thailand on June 9, 2022, was a breakthrough moment for the industry.  Not only are farmers and others in the industry elated that such a step was taken, it has triggered the establishment of an abundance of cannabis dispensaries in Bangkok and other popular domestic and international tourist destinations in Thailand, including Chiang Mai, Pattaya, Phuket, and many islands. Vulnerable populations, such as children, accessing cannabis has also become a hot-button issue. Thailand’s Ministry of Public Health (MOPH) was initially criticized by some for its policy of allowing cannabis to be sold with few restrictions. On June 17, 2022, the MOPH followed up with the Announcement Re: Controlled Herbs (Cannabis) under the Thai Traditional Medical Knowledge Act, which seemed to implement a viable mechanism to regulate cannabis dispensaries. This announcement contained prohibitions on selling cannabis to vulnerable populations (minors, expectant women, and breastfeeding mothers) and on smoking cannabis in public. Furthermore, the draft Cannabis and Hemp Act includes provisions related to sales and distribution channels and advertisements for particular dispensaries. However, the draft act has been delayed due to disagreements among some political parties during the reading of the legislation, and is unlikely to be implemented in 2022 as had been widely expected.  The tug-of-war among the political parties has caused concerns about whether the country’s recent liberalized cannabis policy will be revisited and cannabis relisted as a narcotic. With this uncertainty over when the draft Cannabis and Hemp Act will be implemented, the MOPH has focused on identifying gaps in current regulation that might allow the misuse of cannabis. The minister of the MOPH has announced that the MOPH announcement of June 17, 2022, will be repealed and replaced by the November 11, 2022, Announcement Re: Controlled Herbs (Cannabis).
Read More
November 14, 2022
Following the delisting of cannabis grown in Thailand as a narcotic substance on June 9, 2022, many have explored the applications of cannabis in various fields, including medicine, healthcare, food products, cosmetics, and animal feed. For example, a poultry farm in northern Thailand conducted an experiment jointly with Chiang Mai University, mixing crushed cannabis into poultry feed and water. The experiment showed several benefits of this cannabis feed. Birds that were fed cannabis had lower mortality rates and achieved superior body mass, with increased levels of protein, fat, and moisture in the meat, leading to this method of organic bird farming yielding higher profits. Despite the results of this experiment, the mechanisms and action of cannabis in animal feed are still not yet fully understood, and there are concerns about the possible effects on human health of consuming cannabis-fed poultry. Until recently, cannabis regulations focused solely on the safety of use by humans, and there were no regulations on the use of cannabis in animals. However, on October 11, 2022, the Department of Livestock Development (DLD) published Notification Re: Guidelines on the Use of Hemp and Marijuana as Especially Controlled Animal Feed or Their Use as Ingredients in Especially Controlled Animal Feed in the Government Gazette. In general, the DLD notification requires that animal feed containing cannabis be shown to benefit the animals without causing concern for their safety. According to the Animal Feed Quality Control Act B.E. 2558 (2015), especially controlled animal feed must be registered before it can be manufactured domestically or imported into Thailand. The DLD notification lays down the following evaluation criteria for registration of animal feed containing cannabis: It is prohibited to use cannabis (both hemp and marijuana) apexes (i.e., leaf tips), inflorescence, or seeds—including extracts from apexes, inflorescence, or seeds—as especially controlled animal
Read More
October 14, 2022
Interest in organic farming, soil health, and regenerative agriculture has increased rapidly in recent years, and the demand for biological and organic fertilizers has accordingly undergone dramatic growth. Biological fertilizers contain specific levels of microorganisms (such as nitrogen-fixing bacteria); organic fertilizers similarly contain microorganisms and typically come from animals and plants, such as livestock manure and crop residues. Although responsible fertilizer use is still necessary to prevent unintended effects, these “living fertilizers” can boost yields and promote plant productivity without many of the adverse environmental effects and safety concerns of chemical fertilizers. This makes them highly sought after for organic farming, and prized by agricultural operators looking to promote soil health as a bedrock of sustainable agricultural practices. As the global trade for organic and biological fertilizers has scaled up, producers and agribusiness companies have expanded organic and biological fertilizer offerings to new markets. Not only do different countries have their own regulations for fertilizers in general, but they also often have specific requirements and rules for biological and organic fertilizers. This guide provides fertilizer producers and traders with an overview of the legal landscape for these fertilizers in three major Southeast Asian markets so that businesses can make their fertilizers available and foster sustainable agricultural practices in the region. The full Biological and Organic Fertilizers in Indonesia, Thailand, and Vietnam guide can be downloaded through the button below.
Read More